🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Cellenkos will present Phase 1b data on CK0804 in Myelofibrosis at the ASH Annual Meeting 2024. More Info: pryzm.ozmosi.com/product/25960 $XBI $IBB $XPH $PPH

Lucia Masarova, MD presented phase 1b trial of CK0804 #tregs #Cellenkos in #myelofibrosis unresponsive to prior therapy. #SVR35 in 16%; #SVR25 in 33% at EOC6; #TSS50 in 66%. Decreased inflammatory cytokines including. #TGFbeta #ASH2024

Cellenkos releases Phase 1b data at ASH 2024 highlighting T-Regulatory Cell Therapy candidate CK0804 for Myelofibrosis treatment. More Info: pryzm.ozmosi.com/product/25960 $XBI $IBB $XPH $PPH

pharmatimes.com/news/cellenkos…

China’s NMPA clears country’s first mesenchymal stem cell therapy bioworld.com/articles/716073 #biotech #pharma @CytoNiche2018

🚨Highlights from #ASH2024! Dr Nikki Granacher reviews advancements in MPN care: - TP53 mutations linked to risk and prognosis - CK0804: Durable symptom control in MF with cellular therapy - Navtemadlin: Improves disease burden and biomarkers - Nuvisertib: Promising clinical

We’re heading to San Francisco for the 43rd Annual J.P. Morgan Healthcare Conference next week! We’re looking forward to catching up with peers in the #biotech, #biopharma & investor communities. Let’s connect! bit.ly/40dFQ9Q #JPM2025

According to data presented by Lucia Masarova, MD, CXCR4-enriched T regulatory cell therapy (CK0804) as an addition to RUX treatment demonstrated initial safety and promising clinical activity for patients with myelofibrosis receiving RUX. Learn more: hmpgloballearningnetwork.com/site/onc/confe…

Cellenkos Therapeutics tests rare blood cancer therapeutics - InnovationMap houston.innovationmap.com/cellenkos-ther…

Thank you to InnovationMap for profiling our work developing off the shelf #Treg cell therapies for patients with serious inflammatory & autoimmune conditions such as #AplasticAnemia and #myelofibrosis. We're proud to be part of Houston’s biotech ecosystem. Read the story below!

frontiersin.org/journals/immun…

📝 Just published! Catch up on a new publication showcasing the potential of umbilical cord-blood derived #Treg cell therapy to downregulate systemic inflammation in a translational model of systemic lupus erythematous (#SLE). More here: bit.ly/4jKcAk2

#DYK? #AplasticAnemia is a serious #RareDisease where the bone marrow does not produce enough blood cells. Patients experience burdensome symptoms that diminish their quality of life. Learn more here: bit.ly/42WjYme.

Discovered this event - Orphan Drug Congress on # Will you be there? terrapinn.com/e/10887 #

drugtargetreview.com/article/156747…

Cutting-edge cell therapy is here! Dr. Simrit Parmar joins #CellAndGenePodcast to talk about Cellenkos’ breakthrough in umbilical cord blood-derived Treg therapies. Learn about the latest CK0804 trial & what’s coming in 2025! Erin Harris Cell&Gene simrit parmar

The amazing inspiring Dr. Parmar (⁦Lurie Cancer Center⁩ alum) on her start-up - how did it all start? And how challenging to get it off the ground in the cellular therapy space? Just a fascinating journey - you’ll listen to this one twice. Clip and link: podcasts.apple.com/us/podcast/hea…

Cellenkos Announces US FDA Orphan Drug Designation Granted to CK0801 (Allogeneic Cord Blood derived T regulatory C... prn.to/4cGzshm

Cellenkos Inc. and King Faisal Specialist Hospital & Research Centre, Sign Strategic MOU to Advance T Regulatory C... prn.to/3YXBIen